drugset / Trial / NCT02146079

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

NCT02146079

Phase 1 Completed 44 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and tolerability of semaglutide in healthy male Japanese and Caucasian subjects.

Timeline

Start
2014-05-21
Primary completion
2014-10-20
Completion
2014-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 0.5 mg Subcutaneous
Subject Semaglutide Peptide 1 mg Subcutaneous